Reviva Pharmaceuticals Holdings, INC 10-Q quarterly reports

Reviva Pharmaceuticals Holdings, Inc. reported its Q2 2026 results, highlighting continued net losses, a Nasdaq delisting, and a move to the OTCQB Venture Market, while advancing its brilaroxazine development program.

Reviva Pharmaceuticals reports Q1 2026 results, detailing a net loss of $3.2 million and significant cash burn, while preparing for Nasdaq delisting and transition to OTCQB.

Reviva Pharmaceuticals Holdings, Inc. reported a reduced net loss in Q3 2025 and advanced its lead drug candidate brilaroxazine, but faces Nasdaq delisting concerns and ongoing liquidity challenges.

Reviva Pharmaceuticals Holdings, Inc. reported a reduced net loss and successful clinical trial completions for brilaroxazine, but raised $9.7 million in new capital while facing substantial doubt about its ability to continue as a going concern and Nasdaq delisting threats.

Reviva Pharmaceuticals announces its Q1 2025 financial results, highlighting the progress of its lead drug candidate, brilaroxazine, and the need for additional funding to continue operations.

Reviva Pharmaceuticals' Q3 2024 report highlights a net loss, ongoing clinical trials for brilaroxazine, and recent capital raises to support operations.

Reviva Pharmaceuticals' Q2 2024 report details a net loss of $15.3 million, ongoing clinical trials, and a restatement of prior financial results.

Reviva Pharmaceuticals reported a net loss of $7.4 million for the first quarter of 2024, highlighting ongoing clinical development expenses and the need for additional capital.